01—Abstract
Summary
Summary of the 10-Q filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported a significant turnaround in the first quarter of 2025, with net income swinging from a loss of $113 milliona in Q1 2024 to a profit of $1.73 billion in Q1 2025.
This substantial improvement was driven by a robust increase in total revenues, which grew by 9% year-over-year to $8.15 billionb, primarily fueled by an 11% rise in product sales to $7.87 billion. The company's operating income also saw a healthy increase of 19% to $1.18 billion, reflecting effective cost management despite a notable $800 million impairment charge related to Otezla. The balance sheet shows a decrease in cash and cash equivalents to $8.81 billion from $11.97 billion, alongside a reduction in total debt.
The company continues to prioritize shareholder returns, declaring a quarterly dividend of $2.38c per share, underscoring its commitment to financial health and shareholder value. Investors should note the ongoing legal proceedings, particularly the significant U.S. tax litigation, which remains a key area of focus, although a decision is not expected until the second half of 2026.
02—Key points
Key Highlights
- Amgen reported a strong Q1 2025 with net income of $1.73 billion, a significant improvement from a net loss of $113 million in Q1 2024.
- Total revenues increased by 9% to $8.15 billion, driven by an 11% rise in product sales to $7.87 billion, with notable growth in key products like Repatha, EVENITY, and BLINCYTO.
- Operating income grew by 19% to $1.18 billion, demonstrating improved operational efficiency.
- The company incurred an $800 million intangible asset impairment charge related to Otezla due to its selection for Medicare price setting under the IRA.
- Cash and cash equivalents decreased to $8.81 billion, while total debt also saw a reduction during the quarter.
- Amgen declared a quarterly cash dividend of $2.38 per share, signaling continued commitment to returning capital to shareholders.
- Significant U.S. tax litigation regarding profit allocation between the U.S. and Puerto Rico remains ongoing, with a U.S. Tax Court decision not expected before the second half of 2026.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Amgen Inc kept $0.21.
- Revenue$8.15B100.0%
- Cost of revenue−$2.97B36.4%
- Gross profit$5.18B63.6%
- Operating costs−$4.00B49.1%
- Operating income$1.18B14.5%
- Interest, other & tax$552.0M6.8%
- Net income$1.73B21.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 2, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $8.15B$7.45B | +9.4% |
| Cost of Revenue | $2.97B$3.20B | −7.2% |
| Gross Profit | $5.18B$4.25B | +22.0% |
| SG&A Expenses | $1.69B$1.81B | −6.7% |
| Operating Expenses | $6.97B$6.46B | +8.0% |
| Operating Income | $1.18B$991.00M | +18.9% |
| Interest Expense | $723.00M$824.00M | −12.3% |
| Net Income | $1.73B-$113.00M | +1631.0% |
| EPS (Basic) | $3.22$-0.21 | +1633.3% |
| EPS (Diluted) | $3.20$-0.21 | +1623.8% |
| Shares Outstanding (Basic) | 538.00M536.00M | +0.4% |
| Shares Outstanding (Diluted) | 541.00M536.00M | +0.9% |
05—Questions
Frequently Asked Questions
What is the primary driver of Amgen's revenue growth in Q1 2025?
The primary driver of Amgen's revenue growth in Q1 2025 was a strong increase in product sales, which rose by 11% year-over-year to $7.87 billion. This growth was supported by volume increases in key products such as Repatha, EVENITY, BLINCYTO, and TEZSPIRE.
What is the impact of the Otezla intangible asset impairment charge?
Amgen recorded an $800 million intangible asset impairment charge in Q1 2025 related to its product Otezla. This was triggered by Otezla's selection for Medicare price setting under the Inflation Reduction Act (IRA), which impacted the estimated future cash flows for the product in the United States. While this charge affected operating expenses, the company's overall net income remained strongly positive due to robust revenue growth.
What is the status of the U.S. tax litigation?
Amgen is actively contesting significant tax disputes with the IRS concerning the allocation of profits between the U.S. and Puerto Rico for the years 2010-2015. The trial concluded in January 2025, and the company expects a decision from the U.S. Tax Court no earlier than the second half of 2026. While the company believes its tax positions are valid, the outcome could potentially result in substantial tax liabilities.
How is Amgen managing its debt and returning capital to shareholders?
Amgen demonstrated a reduction in its total debt during the quarter. The company also continues its commitment to shareholder returns by declaring a quarterly cash dividend of $2.38 per share. Furthermore, Amgen has a remaining authorization of $6.8 billion under its stock repurchase program, though no shares were repurchased in the first quarter of 2025.
06—Continue